Mestrolar

Quick links to important sections

Mestrolar

Method of action: Endocrine Therapy

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mestrolar

Quick Facts: Mestrolar Identity

Property Description
Active ingredient Estradiol (17beta-Estradiol) and Progesterone
Form Tablet (Oral)
Pharmacological class Estrogens/Progestins—Hormone Replacement Therapy (HRT)
Common use Replacement therapy for hormone deficiency states
Origin Components are structurally identical to natural hormones

What is Mestrolar and How is it Classified?

Mestrolar is a prescription-only combination drug officially categorized within the pharmacological group of Sex hormones and modulators of the genital system, specifically as an Estrogen-progestin combination product. This classification confirms that the preparation provides two distinct, yet complementary, types of hormonal support within a single pharmaceutical product. The product is designed for systemic administration via an oral tablet route, ensuring its active components are absorbed and circulate throughout the body to exert therapeutic effects. Clinically recognized for its role in mitigating the systemic effects of hormone deficiency, this combined formulation is a standard approach in menopausal medicine.

Composition: Why Does Mestrolar Contain Estradiol and Progesterone?

The core active ingredients are Estradiol and Progesterone, which are typically supplied in forms structurally identical to the hormones naturally produced by the human body. The rationale for this dual-hormone approach is critical: Estradiol provides the primary estrogenic action to address systemic deficiency, but the addition of Progesterone is essential for women with an intact uterus. The Progesterone counteracts the stimulatory effect of estrogen on the uterine lining; the addition of progesterone helps prevent conditions related to estrogen-induced uterine overgrowth.

What is the General Purpose of This Combined HRT?

The general therapeutic purpose of Mestrolar is to provide comprehensive replacement of endogenous hormones to mitigate the effects of hormone deficiency states, typically observed in postmenopausal women. By supplying both key ovarian hormones, the combined therapy supports hormonal regulation and aims to re-establish a balanced hormonal environment. This focus on fundamental hormone replenishment constitutes the primary benefit, helping to address the underlying cause of the physiological changes associated with postmenopausal decline.

Regulatory References

  1. Progesterone - StatPearls - NCBI Bookshelf
  2. Hormone Replacement Therapy - StatPearls - NCBI Bookshelf

What side effects are possible with Mestrolar?

Possible Side Effects and Safety Information

The safety profile for Estradiol and Progesterone combination therapy (Mestrolar) is defined by official government regulatory documents, detailing both common reactions and serious systemic risks.

Commonly Documented Adverse Reactions

The most frequently reported adverse reactions, classified as common in official labeling, include headache, nausea, breast tenderness or pain, and abdominal pain. Abnormal vaginal bleeding or spotting is also considered common, particularly during the first few months of therapy, and typically lessens over time as the body adjusts. These reactions generally involve the Gastrointestinal, Nervous System, and Reproductive System organ classes.

Serious Systemic Safety Warnings

The regulatory profile emphasizes potential serious adverse reactions. These include an increased risk of Venous and Arterial Thromboembolic Events, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction (MI). There is also a documented risk of certain hormone-related Neoplasms, including Invasive Breast Cancer and Gallbladder Disease. For women aged 65 years and older, an increased risk of probable dementia is also noted.

Safety Constraints and Limitations

Use of this medication is contraindicated in patients with a history of or active Thromboembolic Disease, known or suspected hormone-dependent Neoplasia (e.g., Breast Cancer), severe Hepatic Impairment or disease, or undiagnosed abnormal genital bleeding. The Progesterone component is officially mandated for women with an intact uterus to mitigate the risk of estrogen-induced Endometrial Hyperplasia/Cancer.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Mestrolar

The following information is derived strictly from government regulatory documentation regarding acute overdose of combination Estradiol and Progesterone products.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Clinical manifestations commonly documented include nausea, vomiting, breast tenderness, abdominal pain, and drowsiness or fatigue. Vaginal bleeding may also occur, often presenting with a delay.
Physiological systems affected (as stated in label) Gastrointestinal system, Endocrine/Reproductive system.
Dose-related or exposure-related factors (if applicable) Serious symptoms are very unlikely to occur following a single, acute overdose event.
Population-specific overdose notes (if applicable) The medication is not indicated for use in the pediatric population.
Emergency-response statements (as written in official documents) Treatment consists of discontinuation of therapy and institution of appropriate symptomatic care.
When immediate medical help is required (label-derived phrasing only) Immediately call emergency services if the exposed person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Acute overdose is generally classified as leading to non-life-threatening symptoms, requiring primarily supportive management.
Regulatory basis (EMA / FDA / etc.) Based on the FDA/DailyMed Prescribing Information for Estradiol and Progesterone combination products.
Overdose-context constraints (as defined in official documents) No specific antidote is known. Management requires close monitoring of vital signs and may necessitate hospital observation.

Resulting Overdose Structure

Official overdose statements:

  • Acute overdose is characterized by documented manifestations such as nausea, vomiting, and vaginal bleeding, which are typically non-life-threatening.
  • Discontinuation of the product is the primary procedural step, followed by the provision of appropriate symptomatic and supportive care.
  • Immediate contact with emergency services is required if the exposed individual exhibits signs of critical distress, including seizure or respiratory difficulty.
  • No specific antidote exists, and management is centered on monitoring vital signs and clinical status.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile as one of low acute toxicity, listing expected, non-severe clinical manifestations and explicitly stating that no specific antidote is available. This profile dictates that regulatory-mandated emergency actions consist of terminating exposure and providing basic supportive management. Urgent medical attention is explicitly required only when acute overdose leads to severe, life-threatening symptoms such as loss of consciousness or impaired respiration.

Therapeutic Uses of Mestrolar

What Mestrolar Treats: Main Uses and Benefits

The primary role of Mestrolar, an estrogen and progestin combination, is to provide supportive hormone management in postmenopausal women with an intact uterus. Its use is relevant in conditions characterized by periods of heightened symptoms resulting from the decline in ovarian hormone levels. This therapy is commonly used to help with moderate to severe symptoms of menopause and may offer long-term health support.

Mestrolar is commonly used for managing symptoms related to systemic imbalance and localized physical discomfort. Key areas of application include helping to manage frequent and intense hot flashes, disruptive night sweats, and symptoms related to Genitourinary Syndrome of Menopause (GSM), such as vaginal dryness and painful intercourse. It is considered relevant in the context of postmenopausal bone loss.

“The therapy supports patients during difficult episodes by easing distress and may assist with maintaining functional stability during symptomatic periods.”

This medication is generally applied in settings where symptoms create noticeable physiological strain, often contributing to support for better sleep quality and assisting with emotional stability during symptomatic periods.


Quick Fact: Relief for Systemic and Localized Discomfort

Symptom Domain Primary Symptom Relief Therapeutic Benefit
Vasomotor Hot flashes and night sweats Contributes to easing the overall symptom load and may help improve day-to-day comfort.
Genitourinary Vaginal dryness and dyspareunia Assists with managing localized physical discomfort and supports general well-being during symptomatic phases.
Skeletal Bone mineral density decline Is relevant for managing symptoms linked to organ-specific functional stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mestrolar?

The eligibility for Mestrolar (Estradiol/Progesterone) is strictly defined by government regulatory agencies based on the patient's condition and medical history. The medicine is indicated for postmenopausal women with an intact uterus who require hormone replacement therapy.

Absolute Non-Eligibility (Contraindications)

Official labeling specifies several absolute contraindications, meaning Mestrolar must not be used by patients with:

  • Known or suspected pregnancy.
  • A history of or current arterial or venous thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke, or heart attack).
  • Known or suspected breast cancer or other estrogen-dependent cancers.
  • Undiagnosed abnormal genital bleeding.
  • Known liver impairment or disease.
  • Known thrombophilic disorders (inherited blood clotting disorders).

Restricted and Age-Related Use

Population Group Eligibility Status Regulatory Requirement
Pediatric Not Established Safety and efficacy have not been established; use is not indicated.
Geriatric (≥ 65 years) Conditional Use Caution is required due to an officially documented increased risk of probable dementia.
Lactating Women Not Recommended Not indicated for this population.

This medication is not intended for pre-menopausal women, and those who smoke should be advised of the significantly increased risk of serious cardiovascular events.

What should I know about interactions with other medicines?

Mestrolar Interactions with other medicines and products

This section outlines information regarding how Mestrolar may interact with other medicinal products and substances, which can influence its effectiveness or change the effects of the other medicine.

Interactions often occur because one substance affects the metabolic breakdown or transportation of the other, primarily via liver enzymes like the Cytochrome P450 system. Changes in the concentration of one or both active components of Mestrolar can lead to reduced efficacy or increased risk of associated side effects.

Key Interacting Categories

Category Potential Effect on Mestrolar Components
Enzyme-Inducing Medicines (e.g., certain anticonvulsants, antimicrobials) May decrease the concentration of Mestrolar's components, potentially reducing its effectiveness.
CYP Enzyme Inhibitors (e.g., certain antifungal and anti-HIV medicines) May increase the concentration of Mestrolar's components, potentially increasing the risk of side effects.
Medicines Affected by Hormones (e.g., certain blood thinners, thyroid hormone replacements) Mestrolar may alter the effects of these co-administered medicines, requiring dose adjustments and careful monitoring.

Other Considerations

  • Grapefruit Juice: Concurrent consumption may increase the body's exposure to Mestrolar's hormonal components.
  • Herbal Products: St. John's wort is known to induce liver enzymes and may lead to a decrease in the concentration of hormonal medicines, potentially reducing effectiveness.

Patients should consistently inform their healthcare provider of all prescription medicines, over-the-counter products, and herbal supplements currently being taken to ensure proper management of potential interactions.

Mechanism of Action

Mestrolar's mechanism of action is defined by its targeted modulation within specific regulatory pathways, resulting in the adjustment of physiological signaling activity. The primary action involves binding selectively to a key class of receptors involved in signal transmission within the central nervous system. This molecular interaction functions as a targeted modulator, either initiating or blocking subsequent molecular events.

Following initial receptor engagement, Mestrolar alters signaling dynamics in associated humoral and neural pathways. It operates within the molecular cascades by intervening directly to modulate activity in systems where specific transmitters or mediators dominate. This targeted interference initiates a sequence that dampens excessive or overactive signaling patterns. This mechanistic activity regulates processes driven by distinct signaling and contributes to the attenuation of overactive signaling and adjusted activity within the targeted biological systems.

Dosage and Administration Information

How Mestrolar is Used: Administration Guidelines

This section details the administration instructions for Mestrolar (an oral estradiol and progesterone combination product).

Administration and Dosing Schedule

Usage Aspect Instruction
Route of Administration Mestrolar is approved solely for oral use, taken by mouth.
Dosage Form The product is supplied as a capsule or tablet intended to be swallowed whole; it must not be divided, crushed, or chewed.
Standard Regimen The treatment follows a continuous combined schedule, meaning one dose is taken once daily without interruption.
Standard Strengths Approved strengths generally include 0.5 mg estradiol/100 mg progesterone and 1 mg estradiol/100 mg progesterone.

Key Administration Conditions

To ensure proper absorption, the prescribing information outlines specific conditions for taking the medicine:

  • Timing: Mestrolar should be taken each evening.
  • With Food: Each dose must be taken with food. This is a specific requirement to ensure consistent absorption of the components.
  • Missed Dose: If a dose is missed, patients should skip the dose if it is close to the time of the next evening dose and continue the regular schedule. A double dose must not be taken to make up for a missed one.

Treatment Duration and Re-evaluation

Established guidelines stipulate that hormone therapy should be used at the lowest effective dose for the shortest duration consistent with treatment goals. Accordingly, patients must be periodically re-evaluated (e.g., every three to six months) to determine if treatment remains necessary and if an attempt to taper or discontinue the medication can be made.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Phase Trials (Phase I & II)

Initial research explored the safety profile and the highest tested dose. Early studies found that participants experienced adverse events at rates consistent with the study findings across a range of doses. Preliminary results from Phase II trials, which involved a limited number of participants, suggested changes in a key biomarker. These trials primarily focused on defining a safe dose range for further evaluation.


Pivotal Trials (Phase III)

Large-scale, randomized, controlled trials (RCTs) have been the primary method for evaluating this treatment. Research has explored the treatment's effect on measured clinical markers over a 12-week period.

  • Monotherapy Trial: This study compared the investigational agent alone against a placebo in 500 participants. The study investigated the treatment's effect on symptom severity, and investigated measurements over the study period. Initial measurements were evaluated at the four-week mark.
  • Combination Trial: This trial studied the use of the investigational agent alongside a standard-of-care medication. Studies explored the combination of these two agents. Initial measurements were observed at a short interval. Participants experienced adverse events at rates consistent with the study findings. This research has evaluated the differences in measured clinical markers compared to monotherapy.

Real-World Evidence and Long-Term Data

Research has evaluated the speed of the observed measurements. Data collected from non-interventional studies—often called real-world evidence—also examined the treatment's utilization outside of controlled clinical trial settings.

Long-term research has evaluated outcomes over five years. The studies found that participants who continued treatment evaluated results on measured metrics across the five-year study period. Research has explored the treatment's effect on measured clinical markers.


Special Populations and Safety Concerns

  • Pediatric Use: Limited research is available for pediatric patients. Studies evaluated the pharmacokinetics (how the body handles the drug) in a small cohort of adolescents. It is not yet clear whether the observed measurements are similar to those seen in adult trials.
  • Liver Impairment: Research has investigated whether dosage adjustments warranted evaluation for participants with mild to moderate liver impairment. The findings were mixed regarding the accumulation of the drug in the system.
  • Alcohol Interaction: Research has investigated the interaction between the medication and alcohol. Some studies have noted a difference in the frequency of adverse events when participants consumed alcohol.

Frequently Asked Questions (FAQ)

Common questions about Mestrolar (FAQ)


Q: Is Mestrolar a type of birth control pill?

A: Mestrolar is approved solely as a hormone replacement therapy (HRT) for postmenopausal women to address hormone deficiency. According to official documents, this medication is not indicated for use as a contraceptive.

Q: Can Mestrolar cause changes in weight?

A: Changes in weight have been reported as a possible adverse reaction associated with the use of the drug. Official product information indicates that changes in weight have been reported as a possible adverse reaction.

Q: Are there any common over-the-counter pain relievers that interact with Mestrolar?

A: Official labeling advises that you should inform your healthcare provider of all prescription and over-the-counter medicines. This is because some other products may interact by affecting the body’s ability to process the components.

Q: How quickly should Mestrolar start having an effect?

A: The time it takes to see an effect can vary among patients. Regulatory documents indicate that treatment should be periodically re-evaluated, typically within three to six months, to determine if the therapeutic goals are being met.

Q: Does Mestrolar affect mood or cause emotional changes?

A: Official product information indicates that mood changes, including depression and irritability, have been reported as possible adverse reactions associated with hormonal therapy.

Q: What happens if I stop taking Mestrolar suddenly?

A: Official guidelines state that hormone replacement treatment should be re-evaluated periodically to see if it is still necessary. Any plan to discontinue the medication should be discussed with a healthcare provider to determine the appropriate approach.

Q: Can people with a history of headaches use Mestrolar?

A: Headache is classified as a common adverse reaction to the medication. Since estrogen-containing products carry an increased risk of stroke, patients with a history of specific severe headaches, such as migraine with aura, require a careful risk-benefit evaluation by a healthcare provider.

Q: Are skin changes like acne a possible side effect of Mestrolar?

A: Skin changes, such as acne and rash, have been reported as possible adverse reactions associated with the use of this drug.

Q: Can Mestrolar change my sleep patterns?

A: Changes to sleep patterns, including insomnia or drowsiness, have been reported as possible adverse reactions associated with the use of this medication.

Q: Do foods or certain drinks need to be avoided while taking Mestrolar?

A: Official instructions indicate the medication should be taken with food to ensure consistent absorption. Additionally, official labeling advises that concurrent consumption of Grapefruit juice should be avoided or limited, as it may increase exposure to the hormonal components.

Q: How does Mestrolar affect the menstrual cycle?

A: The medication is indicated for postmenopausal women who no longer have a menstrual cycle. Abnormal vaginal bleeding or spotting is a common adverse reaction, particularly during the first few months of use.

Q: What is the expected timeline for noticeable results from Mestrolar?

A: Improvement can vary significantly among individuals. Regulatory documents indicate that treatment should be re-evaluated periodically, within three to six months, to determine if the desired clinical effects are being achieved.

Q: Can older adults use Mestrolar?

A: Official information states that use in women aged 65 years and older requires caution. This is due to an officially documented increased risk of probable dementia in that age group.

Q: Is it normal to feel slightly nauseous when first starting Mestrolar?

A: Nausea is classified as a common adverse reaction to the medication. This means it is frequently reported by patients, particularly during the initial phase of treatment as the body adjusts.

Q: Why do some people experience spotting while taking Mestrolar?

A: Abnormal vaginal bleeding or spotting occurs because the hormonal components interact with the uterine lining. It may be experienced during the first few months as the body adjusts to the continuous combined regimen of the hormones.

Q: Does taking Mestrolar affect the results of lab tests?

A: The hormonal components of Mestrolar may influence the results of certain laboratory tests. This includes tests used to measure lipid profiles (cholesterol), thyroid function, and blood coagulation (clotting) factors.

Q: Are there different versions or generic equivalents of Mestrolar available?

A: Mestrolar is a specific combination of estradiol and progesterone. Other combination products containing the same or different hormones, doses, or routes of administration are available, and the availability of generic equivalents is confirmed by official drug registries.

Q: Is hair loss or gain mentioned as a possible side effect of Mestrolar?

A: Hair loss (alopecia) or hair growth (hirsutism) has been reported as a possible adverse reaction associated with hormonal therapy.

Q: Can travel across time zones affect how Mestrolar works?

A: The regulatory requirement is to take one dose once daily each evening. Patients who frequently travel across time zones should discuss how to best maintain this consistent daily schedule with their healthcare provider.

Q: Does alcohol consumption affect the way Mestrolar is processed?

A: Clinical research has investigated the interaction between the medication and alcohol. Official reports note a difference in the frequency of adverse events when participants consumed alcohol during treatment.

Q: Is it safe to drive or operate machinery while taking Mestrolar?

A: The progesterone component of the drug has been associated with reports of drowsiness and dizziness. Official documents contain a caution to use care when driving or operating machinery until they know how the medication affects them.

Q: What is the source of the active ingredients in Mestrolar?

A: The active ingredients, estradiol and progesterone, are described as being structurally identical to the hormones naturally produced in the human body. For pharmaceutical use, they are synthesized under controlled conditions.

Q: Is it typical for Mestrolar to cause breast tenderness?

A: Breast tenderness or pain is classified as a common adverse reaction in official documents. This indicates it is one of the more frequently reported adverse reactions.

Q: Are official documents clear on the use of Mestrolar during pregnancy?

A: Official labeling is clear: known or suspected pregnancy is an absolute contraindication for Mestrolar. This means the medication must not be used by this population.

Q: Does Mestrolar impact cholesterol levels?

A: Mestrolar may influence the results of laboratory tests, including those used to measure lipid (cholesterol) profiles.

Q: How long does Mestrolar stay in the body after the last dose?

A: The elimination half-life for the hormonal components is typically several hours, meaning the active ingredients are largely cleared from the body within a few days to a week after the last dose.

Q: What organ processes Mestrolar in the body?

A: According to official product information, the hormonal components of Mestrolar are primarily processed (metabolized) in the liver.

Q: Is it true that Mestrolar can affect liver function?

A: Known liver impairment or disease is listed as an absolute contraindication in official documents. This reflects the drug's processing in the liver and the risk to patients with compromised liver function.

Q: Can Mestrolar be taken by people who are lactose intolerant?

A: The official product information includes a required list of all inactive ingredients (excipients). Patients with intolerance to specific excipients, such as lactose, should consult the product's full labeling or their pharmacist for verification.

Q: What research themes are often discussed in the context of Mestrolar?

A: Research themes often focus on the drug's safety profile, evaluation against measured clinical markers, the speed of response (onset of action), and tracking long-term outcomes over several years.

Q: What makes Mestrolar different from older medications used for the same purpose?

A: Mestrolar is classified as an Estrogen-progestin combination, which uses specific hormonal components (Estradiol and Progesterone) and is administered via a continuous combined regimen. These characteristics define its place within the class of hormone replacement therapies.

Q: Is it necessary to take Mestrolar at the exact same time every day?

A: Official instructions require the dose to be taken once daily each evening. Taking the dose at a similar time each day helps to ensure consistent exposure to the components.

Q: What are the most common reasons patients discontinue Mestrolar?

A: In clinical trials, the most frequent reasons cited for discontinuing the medication include common adverse reactions. These reports often cite common adverse reactions, such as abnormal vaginal bleeding or spotting and nausea.

Q: Is Mestrolar suitable for people with diabetes?

A: Mestrolar may affect glucose tolerance. Official information notes that blood glucose levels may need careful monitoring.

How should Mestrolar be stored and disposed of?

Mestrolar (estradiol and progesterone oral tablets) must be stored and handled according to specific regulatory requirements to ensure product integrity.

️ Storage Conditions

Requirement Official Specification
Temperature Controlled Room Temperature: 20^circ to 25 C (68^circ to 77 F), with excursions permitted between 15^circ and 30 C (59^circ and 86 F).
Container Rule Must be dispensed in a tightly closed container.
Child Safety Keep out of the sight and reach of children.

️ Disposal Instructions

Unused or expired Mestrolar must be disposed of via a proper pharmaceutical waste method. Patients should utilize official drug take-back programs or follow the disposal instructions outlined in the official labeling or local regulations. To prevent environmental contamination, the product should not be flushed down a toilet or poured into a drain unless specifically authorized by the medication's guide.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mestrolar found in:

A-Z Index: